Navigation Links
RXi Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell
Date:8/4/2014

MARLBOROUGH, Mass., Aug. 4, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company will ring the NASDAQ Stock Market closing bell on Friday, August 8, 2014. A live webcast will be available at https://new.livestream.com/nasdaq/live

Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO

"Listing on NASDAQ has allowed us to gain access to a broader institutional investment community," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "Commemorating this accomplishment, by ringing the NASDAQ closing bell, is a good reminder of the progress we have already achieved with developing our self-delivering RNAi-based (sd-rxRNA®) technology platform into commercially viable assets.  We would like to thank our shareholders, patients, volunteers and advisors for their support in the Company's development."

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi (sd-rxRNA®) platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to down-regulate the expression of specific genes that may be over-expressed in disease conditions. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, a self-delivering RNAi compound (sd-rxRNA®), entered into human clinical trials in June 2012 and is currently being evaluated in Phase 2 clinical trials to reduce the formation of dermal scars (fibrosis).  RXI-109 is designed to reduce the expression of connective tissue growth factor (CTGF), a critical regulator of biological pathways involved in fibrosis, including scar formation in the skin.  RXi's sd‑rxRNA oligonucleotides are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. These hybrid oligonucleotide molecules combine the beneficial properties of conventional RNAi and antisense technologies.  This allows sd‑rxRNAs to achieve efficient cellular uptake and potent, long-lasting intracellular activity. For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks and uncertainties:  the risk that we may not be able to successfully develop our candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based products; risks that the development process for our product candidates may be delayed, risks related to the development and commercialization of products by our competitors, the risk related to our ability to control the timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com


'/>"/>
SOURCE RXi Pharmaceuticals Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars
2. Galmed Pharmaceuticals Reports First Half 2014 Financial Results
3. SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services
4. Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC
5. Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014
6. ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of a Vaginal Gel for the Prevention of HIV Transmission to Women
7. Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria
8. Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
9. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
10. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
11. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... PA (PRWEB) , ... December 01, 2016 , ... ... through industry-wide collaboration, standardization and a beautiful technology experience. All three tenets were on ... than 100 clinical trial leaders from over 40 sponsor, CRO and site organizations to ...
(Date:12/2/2016)... Washington, DC (PRWEB) , ... ... ... Technologies Consortium™ (ETC), a consortium of pharmaceutical and biotechnology companies dedicated to ... is seeking companies interested in supplying a vendor-supported, portable online UHPLC, with ...
(Date:12/2/2016)... Dec. 1, 2016   SurePure, Inc. (OTCQB: ... that the Company has concluded an agreement with Tamarack ... a 90-day period to acquire units of the Company,s ... USD 3.7 million.  Concurrently with the ... under which Tamarack will seek regulatory approvals in ...
(Date:12/2/2016)... RICHMOND, BC , Dec. 2, 2016 /PRNewswire/ - bioLytical Laboratories, a world leader ... Test, to Kenya,s Pharmaceutical Association members. (Photo: ... ... , , ... Initiative (CHAI) and the Kenya Pharmaceutical Association (KPA) to introduce the INSTI HIV Self ...
Breaking Biology Technology:
(Date:11/30/2016)... 2016  higi SH llc (higi) announced today ... national brands, industry thought-leaders and celebrity influencers looking ... for taking steps to live healthier, more active ... higi has built the largest self-screening health station ... people who have conducted over 185 million biometric ...
(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...
(Date:11/21/2016)...   Neurotechnology , a provider of high-precision ... that the MegaMatcher On Card fingerprint matching algorithm ... NIST Minutiae Interoperability Exchange (MINEX) III ... of the evaluation protocol. The ... fingerprint templates used to establish compliance of template ...
Breaking Biology News(10 mins):